Algeria is currently undergoing a significant transformation in its healthcare infrastructure. With the "Plan National de Développement Sanitaire," the Algerian government is prioritizing the modernization of medical laboratories and the localization of diagnostic capabilities. The demand for Automated Molecular Testing Systems in Algeria has surged, driven by the need to manage infectious diseases, monitor genetic disorders, and support the burgeoning pharmaceutical industry in hubs like Algiers, Oran, and Constantine.
Supplying the Algerian market requires more than just high-tech hardware; it demands an understanding of local regulatory frameworks set by the Agence Nationale des Produits Pharmaceutiques (ANPP). Global enterprises and local distributors are seeking suppliers who can provide integrated solutions—combining nucleic acid extraction, amplification, and data analysis into a seamless, automated workflow. This reduces human error, crucial for high-throughput state laboratories like the Pasteur Institute of Algeria.
The global trajectory for molecular testing is moving toward Hyper-Automation and AI-Integrated Diagnostics. BioX Medical is at the forefront of this evolution, developing systems that go beyond traditional PCR.
Shenzhen BioX Medical Co., Ltd. is a professional manufacturer specializing in molecular diagnostic analysis systems, genetic testing solutions, and clinical laboratory equipment. Established in 2017, the company is headquartered in Shenzhen, China, a leading center for biotechnology innovation, medical device development, and advanced manufacturing.
With a modern manufacturing facility covering more than 9,000 square meters and a workforce of over 200 employees, BioX Medical is dedicated to the research, development, production, and supply of molecular diagnostic technologies for clinical laboratories, hospitals, research institutions, public health organizations, and biotechnology companies worldwide.
The company's product portfolio includes molecular diagnostic analysis systems, nucleic acid testing platforms, genetic analysis systems, pathogen detection solutions, biomarker analysis equipment, automated laboratory testing systems, and precision medicine support technologies. By integrating advanced automation, data management capabilities, and laboratory workflow optimization, BioX Medical develops solutions designed to improve testing efficiency, analytical accuracy, and operational reliability.
We understand that entering the Algeria market requires more than just shipping a product. BioX Medical provides comprehensive localization support, including:
For global enterprises seeking OEM/ODM services, our Shenzhen-based R&D team can customize hardware and software to meet specific national health mandates or private laboratory requirements.
Automation significantly increases throughput, reduces the risk of cross-contamination, and standardizes results across different operators. In the context of Algeria's growing healthcare needs, it allows smaller provincial labs to perform complex diagnostics with high precision.
Our systems are designed to international ISO 13485 standards and carry CE-IVD marking. We work closely with Algerian distributors to prepare the necessary documentation for ANPP (Agence Nationale des Produits Pharmaceutiques) registration.
Yes, through our network of certified partners and distributors in Algeria, we offer installation, operator training, and preventative maintenance services to ensure clinical continuity.
Absolutely. Our molecular testing platforms feature open API protocols that allow seamless integration with modern LIS, facilitating digital health record management across the Algerian medical network.
BioX Medical
